All posts by medical

Combining genetics, herd health and compact calving on a Co. Kerry dairy farm – Agriland

Dairy farmer John P. Galvin milks 80 cows in a compact spring-calving system overlooking the Dingle Peninsula in Lispole, Co. Kerry.

Galvins land goes right down to the Atlantic Ocean and receives 1,600-1,700mm of rainfall on an annual basis.

Last year, John sold 477kg of milk solids from each cow in his herd to the Kerry Group at 4.22% fat and 3.62% protein.

This output per cow, combined with the high percentages, resulted in a high milk price and helped John greatly in the difficult year that 2016 was.

The herd also featured in the recent top 200 EBI herds in Ireland, sitting in 149th place, with a herd EBI of 129. The herds EBI is balanced between milk (44), fertility (51) and calving (33).

John uses the Munster AI technician service and combines the fresh semen programme with the year one genomic tested sires.

The AI technician, via his handheld, ensures that no inbreeding occurs.

This service allows John to concentrate solely on heat detection during the breeding season knowing that he is receiving the very best genetics available, from a highly skilled Munster AI technician, and completely avoiding inbreeding.

The genetic progress being made is evident from the EBI graph.

The fertility performance of the herd is impressive, with over 85% of the herd calving in just six weeks.

This is achieved through a high submission rate, due to excellent heat detection and a high conception from the AI technician.

Johns heat detection is exceptional; scratch cards are used on the heifers. Cows not detected in heat three weeks into the breeding season are examined and treated.

John monitors the health status of his herd and the efficacy of his vaccination and parasite control programme annually, through the Munster Herd Health programme.

He finds the end-of-year meeting with the Munster vet invaluable, for reviewing his performance and helping him with decisions in which he plans the dry period and the year ahead.

For the past two years, he has carried out Johnes Disease screening through milk recording.

Both these programmes ensure that output is maintained each year and that high genetic breeding stock, with a high health status, can be sold off the farm.

The Kerry-based dairy farmer attributes the performance of his herd to their genetics, health and a compact spring-calving pattern.

Performance is monitored by monthly milk recording from February to November. John is now firmly of the opinion that each cow needs to be contributing to the bottom line for him to maximise his profitability.

The real profit drivers are the mature third lactation plus cows, calving in February.

In 2016, the top 10 mature cows averaged 7,300kg of milk, with 569kg of milk solids at 4.14% fat and 3.65% protein.

A feature of the herd is the consistent level of production between the cows, with no poor performers.

The first milk recording of 2017 was completed on March 7. This allows the early identification of any SCC issues andtheir immediate correction.

This, in turn, allows all cows to reach their full potential over the lactation period.

As all cows and heifers are bred to dairy sires, John has surplus heifers to sell each year as calves, maidens or in-calf heifers.

One can have confidence that these high genetic merit heifers from a high health status herd will perform and remain in the herd for a long time for their new owners.

John has bred a few bulls that have entered AI; the most popular being JKF (IG) Doonmanagh Jacko an FLT son from a great DEU cow.

He is looking forward to producing a genetic gem from his herd on the Dingle peninsula an area that has produced so many footballing legends down through the years.

To find out more about the services offered by Munster AI: Click Here

View original post here:
Combining genetics, herd health and compact calving on a Co. Kerry dairy farm - Agriland

Breakthrough genetics looking at cutting nitrogen leaching – Scoop.co.nz (press release)

Press Release CRV Ambreed

CRV Ambreed has made a genetic discovery that it anticipates will result in a more sustainable dairy industry and potentially reduce nitrogen leaching on New Zealand farms by 20% within 20 years.

Media release

Embargoed to 9am 29 March 2017

Breakthrough genetics looking at cutting nitrogen leaching by 20% in NZ CRV Ambreed

CRV Ambreed has made a genetic discovery that it anticipates will result in a more sustainable dairy industry and potentially reduce nitrogen leaching on New Zealand farms by 20% within 20 years.

In whats thought to be an international first, the dairy herd improvement company has announced it will market bulls that are desirable for traditional traits as well as being genetically superior for a new trait that is related to urea nitrogen in milk.

CRV Ambreed is now selling semen from bulls whose daughters will have reduced concentration of Milk Urea Nitrogen (MUN) under a LowN Sires brand. MUN is a measure of the amount of nitrogen contained as milk urea, and CRV Ambreed R&D Manager Phil Beatson says theres overwhelming international evidence of a direct connection between MUN and the amount of nitrogen excreted in urine when fed different diets.

If this connection carries over, cows bred for lower levels of MUN are expected to excrete less nitrogen in their urine which will, in turn, reduce the amount of nitrogen leached from grazed pasture, Mr Beatson says. Daughters of CRV Ambreeds 2017 LowN Sires could potentially save New Zealand 10 million kilograms in nitrogen leaching a year, based on a national herd number of 6.5 million dairy cattle. He says CRV Ambreeds projections indicate that its possible to breed cattle that will reduce nitrogen leaching by 20% within 20 years.

CRV Ambreed Managing Director Angus Haslett says the firm has been researching the connection between MUN and nitrogen in urine for five years. The link between MUN and lower nitrogen output has been acknowledged before in international research, but this is the first time in the world that genetics for low MUN is being marketed with the aim being to reduce nitrogen leaching.

Hundreds of thousands of straws of semen from a team of more than 20 existing top-performing bulls with desirable genetic makeup for low levels of MUN, known as LowN Sires, are already available for use in 2017.

Mr Haslett says this is a continuation of CRV Ambreeds ongoing work to breed for particular traits that improve New Zealands dairy herds for health and environmental reasons. The future is about using genetics for better breeding and CRV Ambreed has been operating in the future for some time. Farmers are already using genetics to breed cows that are more tolerant to Facial Eczema and for breeding polled calves that will not need costly and time-consuming de-budding.

He says while there is a vast amount of research being conducted and proposed in New Zealand to mitigate nitrogen leaching, it makes sense to look at breeding cows that produce less nitrogen from economic and environmental viewpoints. CRV Ambreed will be the first organisation in New Zealand and possibly the world to provide a long-term genetic solution to nitrogen leaching by identifying and selecting bulls for low MUN genes.

Genetics can produce great gains for farmers, he says. Farmers already choose CRV Ambreed bulls to breed certain traits in their cows, so this is another step on that journey of finding solutions in genetics.

Mr Haslett says there is still research to be done to further test and confirm the genetic development and CRV is working with DairyNZ, AgResearch and Lincoln University on this. CRV Ambreed is very positive about the potential benefits the discovery will deliver for farmers and the nation.

The genetic announcement has been welcomed by major industry players such as DairyNZ. DairyNZ Strategy and Investment Leader for Productivity, Dr Bruce Thorrold, says the potential for farmers to reduce nitrogen leaching by breeding cows with lower urinary nitrogen output is exciting.

If the planned science proves the link between breeding for MUN and urinary nitrogen output, this would give farmers in nitrogen-limited regions such as Canterbury more options to reduce nitrogen leaching without going away from a pasture-based system. Animal breeding would potentially add to gains from DairyNZ investment in research on managing nitrogen inputs, using stand-off and finding plants with lower nitrogen content.

CRV Ambreed has already briefed some of New Zealands regional councils about the discovery as many regional councils are working with farmers to minimise nitrogen leaching.

For more information, visit http://www.crv4all.co.nz/lownsires

About CRV Ambreed:

CRV Ambreed has an overarching ethos of better cows, better life and its business is built around one goal: helping its customers achieve their highest performing herd possible. The company proactively manages ongoing changing market demands by offering innovative solutions tailored to customers needs.

Content Sourced from scoop.co.nz Original url

Continued here:
Breakthrough genetics looking at cutting nitrogen leaching - Scoop.co.nz (press release)

B v B (Fertility Treatment – Paperwork Error) [2017] EWHC 599 (Fam) – Family Law Week

Home > Judgments

Case summary coming soon

Neutral Citation Number: [2017] EWHC 599 (Fam)Date: 23 March 2017

IN THE HIGH COURT OF JUSTICE FAMILY DIVISION

THE HONOURABLE MR JUSTICE PETER JACKSON - - - - - - - - - - - - - - - - -

BETWEEN:

B Applicant - and B and LEEDS TEACHING HOSPITALS NHS TRUSTRespondents B v B (Fertility Treatment: Paperwork Error) - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Mr Karl Rowley QC (instructed by Harrison Drury & Co) appeared on behalf of the Applicant The First Respondent attended in person David Birch (Capsticks) appeared on behalf of the Second Respondent - - - - - - - - - - - - - - - - - - This judgment may be published provided the individuals concerned are not identified.

Failure to comply with this condition may be a contempt of court. J U D G M E N T Mr Justice Peter Jackson: 1.This is an application for a declaration of parentage under s.55A Family Law Act 1986. It is in effect made by a married couple, although he is formally the applicant and the other the first respondent, who seek an order regularising the legal position of the father in relation to a child born to a mother in 2012. The birth was the result of fertility treatment carried out at the Leeds Centre for Reproductive Medicine at Seacroft Hospital, part of the Leeds Teaching Hospitals NHS Trust.

2.The case is yet another where paperwork errors have had potentially serious legal consequences, another case where (to quote the President of the Family Division) medical brilliance has been allied with administrative incompetence. However, the couple has nothing but praise for the medical treatment they received, leading to the birth of a much-loved child. The Trust, for its part, has explained what went wrong, done everything it can to remedy matters for this family, taken steps to improve its procedures, offered an unreserved apology, and agreed to pay the legal costs.

3.The history, which I need only set out in outline, is set out in the applicant's statement and the statement of Karen Thompson, the lead embryologist and the Trust's 'person responsible' under the legislation.

4.In 2005, the couple (I will call him X and her Y), who were then engaged to be married, approached the Trust for fertility treatment. They underwent counselling and two unsuccessful treatment cycles in March and October 2006. Further treatment cycles (now with donor embryos) occurred in September 2009, March 2010, June 2010, November 2010 and September 2011, and the final one led to the child's birth.

5.The birth was registered, with both parents being named on the birth certificate. Thereafter, in September 2012, the parents married.

6.Following decisions of Cobb J ([2013] EWHC 1418 (Fam)) and Theis J ([2015] EWFC 13), the Human Fertilisation and Embryology Authority (HFEA) directed licensed clinics to audit their paperwork between 2009 and 2014. This clinic's audit covered 36 cases of children born to couples who were not married or in a civil partnership. In two cases, of which this is one, there were no HFEA consent forms (Forms WP and PP), and in one case one form was incomplete.

7.In May 2014, the Trust, no doubt aware of its error, asked the couple to sign forms WP and PP, which they did. Even then, the forms are now missing from the Trust's records. They could in any case have no independent effect as they date from after the treatment.

8.In February 2015, the Trust finally informed the couple of the problem, and in December 2016 these proceedings were issued.

The agreed fatherhood conditions 9.The Human Fertilisation and Embryology Act 2008 came into effect on 5 April 2009. From that date the non-birth partner in a couple who were not married or in a civil partnership will only be recognised as the legal parent of a child born of licensed fertility treatment using donor gametes in the UK if the 'agreed fatherhood conditions' are fulfilled.

10.Y is in law the child's mother: s.33 HFE Act 2008. Had the couple been married at the time of the treatment, X would automatically be the father: s.35.

11.As they were not married at the time of treatment, s.36 makes X (and no other person: s.38) the father if, but only if, the agreed fatherhood conditions in s.37 are satisfied at the time of the treatment.

12.Section 37 reads, so far as relevant:

37The agreed fatherhood conditions (1)The agreed fatherhood conditions referred to in section 36(b) are met in relation to a man ("M") in relation to treatment provided to W under a licence if, but only if,

(a)M has given the person responsible a notice stating that he consents to being treated as the father of any child resulting from treatment provided to W under the licence,

(b)W has given the person responsible a notice stating that she consents to M being so treated,

(c)neither M nor W has, since giving notice under paragraph (a) or (b), given the person responsible notice of the withdrawal of M's or W's consent to M being so treated,

(d)

(e)

(2)A notice under subsection (1)(a), (b) or (c) must be in writing and must be signed by the person giving it.

(3)

13.Thus, to satisfy the agreed fatherhood conditions, what is required is that

X must have given notice

In advance

In writing and signed

Stating that he consented to being treated as the father of any child

Resulting from the treatment undergone by Y

Under the clinic's licence

And Y must have given notice in the same manner.

The form of consent14.The HFEA is the body responsible for granting licences for treatment. Licences are subject to a range of mandatory conditions, including the obligation to keep proper records: Human Fertilisation and Embryology Act 1990 s.12(1)(d). In April 2009, the HFEA used its statutory powers to give a direction that the consents required under s.37 must be recorded in a specified form: respectively, Form WP ("Your consent to your partner being the legal parent") and Form PP ("Your consent to being the legal parent").

15.The HFEA direction to use the specific forms WP and PP is a condition of the clinic's licence. However, a failure to keep proper records does not of itself invalidate the licence conditions so that treatment ceases to be licensed treatment to which s.37(1) applies. This issue, which arose before Cobb J and Theis J, was resolved by the President in In the matter of the Human Fertilisation and Embryology Act 2008 (Cases A, B, C, D, E, F, G and H) [2015] EWHC 2602 (Fam). I respectfully agree with his conclusions, summarised at paragraph 63:

63.I conclude, therefore, that, in principle:

i) The court can act on parol evidence to establish that a Form WP or a Form PP which cannot be found was in fact properly completed and signed before the treatment began;

ii) The court can 'correct' mistakes in a Form WP or a Form PP either by rectification, where the requirements for that remedy are satisfied, or, where the mistake is obvious on the face of the document, by a process of construction without the need for rectification.

iii) A Form IC, if it is in the form of the Barts Form IC or the MFS Form IC as I have described them above, will, if properly completed and signed before the treatment began, meet the statutory requirements without the need for a Form WP or a Form PP.

iv) It follows from this that the court has the same powers to 'correct' a Form IC as it would have to 'correct' a Form WP or a Form PP.

By way of footnote, the President added:

"I express no views in relation to similar forms used by these or other clinics. I also make clear that nothing I have said should be treated as any encouragement to anyone not to use Form WP and Form PP."

16.The result was that the President found that the internal consent (IC) forms used in those cases were sufficient to satisfy s.37 in Case C (where no WP/PP forms were signed), and that they would have been sufficient in Case E and in Case F (where WP/PP forms had been lost). In addition to these three cases, the later decision of the President in Case M [2016] EWHC 1572 (Fam), in which signed IC forms were found to amount to valid consents, is also in point, as are the similar Cases P, Q, R, T, U, W and X: [2017] EWHC 49 (Fam).

17.To take an example, the father in Case M stated that:

"I am not married to [Y], but acknowledge that she and I are being treated together, and that I will become the legal father of any resulting child."

Y, however did not make a similar declaration in the same form. The IC forms in the three other cases (Cases C, E and F see paragraphs 29-31 of the judgment in Cases A etc.) were in somewhat similar terms to Case M, referring to becoming 'legally responsible', or to becoming 'the father', or 'the legal father'.

18.The question, not answered in the above cases, is whether in very similar overall circumstances, but with different IC forms, the same conclusion should be reached in the present case.

What is being consented to19.The statute requires consent to a man being treated as the father of any child resulting from the relevant licensed treatment. In the nature of things, treatment may be provided in cycles, as happened here. However, this does not mean that consent has in every case to be renewed before each individual treatment cycle, if the reality is that the couple are engaged in a continuous series of treatments to which their earlier consent is intended to apply. This point was considered and explained by the President in Case U: see paragraph 19 of the judgment. This is not to discourage renewal of consent, but what matters is that valid informed consent can be seen to apply to the treatment that is being provided. So, on the facts, a single consent may well apply to a series of treatment cycles. The existence of consent is a question of fact and it will all depend on the facts of the individual case.

What occurred in this case20.I find as facts that (as in Case M and the other similar cases):

(1)The treatment which led to the birth of the child was embarked upon and carried through jointly and with full knowledge by both X and Y.

(2)It was a single course of treatment, albeit that it took place in stages. If I am wrong about that (and it makes no difference to the outcome) the treatment that led to the child's birth was a single course of treatment beginning in 2009.

(3)From the outset and throughout, it was the couple's joint intention, and that of the clinic, that X would be a legal parent of the child. Each parent was aware that this was a matter which, legally, required the signing by each of them of consent forms. Each of them believed that they had signed the relevant forms as legally required and, more generally, had done whatever was needed to ensure that they would both be parents.

(4)From the moment when the pregnancy was confirmed, both X and Y believed that X was the other parent of the child. That remained their belief when the child was born.

(5)X and Y, believing that they were entitled to, and acting in complete good faith, registered the birth of their child, as they believed the child to be, showing both of them on the birth certificates as the child's parents, as they believed themselves to be.

(6)The first they knew that anything might be 'wrong' was when, some years later, they were contacted by the clinic.

(7)X's application to the court is wholeheartedly supported by Y.

21.I further find that as part of the paperwork surrounding their treatment, this couple participated in numerous significant steps:

(1)In December 2005, Y signed HFEA form [007], consenting to being treated together with X: that being the criterion under the 1990 legislation.

(2)In January 2006, X and Y jointly attended counselling to explore the implications of undergoing fertility for themselves and the resulting child.

(3)In December 2005 and June 2006, they jointly signed the Trust's IC form entitled 'Consents For Treatment'. This form states that it covers 'all aspects of treatment'. It ran to 26 pages and has a strong appearance of formality. In its preamble it refers to the need to 'identify individuals who will have the parental responsibility and which person/s will be responsible for the raising of the child or children that may be born as a result of treatment.' By signing the form X and Y specifically acknowledged that they would be responsible for the 'maternal nurturing' and 'paternal nurturing' of the child.

(4)On both dates, X (in Y's presence) signed the IC form consenting to the treatment and stating that:

"I am the husband/partner of [Y] and I consent to the course of treatment outlined above. I understand that I will become the legal father of any resulting child."

(5)On both dates, they jointly signed the IC form stating that they understood that the donor had consented to his not becoming the legal father of the child.

(6)On both dates, they jointly consented to embryo transfer, and to a number of other procedures regarding genetic material.

(7)In November 2006, they again signed an IC form to the same effect as that at (3-6) above.

(8)In 2007, they were seen at the clinic in relation to treatment that did not then take place as a donor pulled out.

(9)On 2 April 2009, they were seen by the embryologist who was then the Trust's responsible person to discuss further treatment with a donor embryo. It was this form of treatment that continued until the successful conception. The very imminent change in the law does not appear to have been discussed.

(10)In April 2009 and November 2009, they again jointly signed an IC form to the same broad effect as at (3-6) above.

(11)There is a note on the IC form just mentioned, written by the member of staff who witnessed the signatures in September and November 2009. It states: 'HFEA form signed'. What this means is unfortunately not known.

(12)In March, June and November 2010, the couple again jointly signed an IC form equivalent to those referred to at (3-6) above, though the form is not now to hand.

(13)In June 2011, they again jointly completed an IC form. This form, which differs from the earlier forms, includes a checklist which itself includes reference to 'The Legalities of Embryo Donation', including 'HFEA', 'Current Law' and 'Birth Certificate'. On this occasion, X and Y both signed a declaration that they understood that donors who had given effective consent would not be the legal parents of any resulting child, and acknowledged that they had been given information about the legalities of embryo donation.

22.Administratively, this is an unhappy picture. It can be seen that the couple signed a mass of consent paperwork in the reasonable belief that the Trust was ensuring that the legal position of themselves and any child born to them was being secured. However, the question is not what they were entitled to expect, but what the legal effect of their actions was.

Argument23.On behalf of the applicant, Mr Rowley QC submits that there is sufficient material for the Court to be able to conclude that the provisions of s.37 are satisfied. In 2005 and 2006 X explicitly confirmed in Y's presence, as witnessed by a member of the clinic's staff, that he would become the legal father. There is then joint confirmation on no fewer than ten occasions between 2005 and 2011 (six of which related to the treatment with donor embryos after September 2009) that

they would be the persons responsible for any child

they were to be responsible for nurturing any child

the donors would not be the legal parents of any child

What, asks Mr Rowley, would have been the purpose of their acknowledging responsibility for the child to the exclusion of the donors unless they knew and intended to convey that they would be the child's legal parents?

24.Mr Rowley fairly draws attention to the fact that the IC form in this case is not the same as that in Case M, or the IC forms in the three other cases (Cases C, E and F see paragraphs 29-31 of the judgment in Case A etc.) which referred to the partner becoming 'legally responsible', or to becoming 'the father', or 'the legal father'.

25.Finally, Mr Rowley urges that any other reading of the documents in this case would leave this family in a deeply unsatisfactory position. The only other way of X becoming the child's legal parent would be by adoption, which is seen as utterly inappropriate as a remedy in cases like this: see Case A, paragraph 71(vii) and Case I, paragraph 24 at [2016] EWHC 791 (Fam).

Conclusion26.I stand back and consider whether, as the statute requires, X gave written notice that he consented to being treated as the father of any resulting child and whether Y gave notice that she too consented to that. Having done so, my conclusion is that these conditions are satisfied in this case. Whether the treatment is considered to have begun in 2006 or 2009, the whole tone was set by the consents signed by X in the presence of Y and the clinic in 2005 and 2006 to his becoming the legal father of any resulting child. Thereafter, at each stage of the treatment, the couple gave signed, written notice to the clinic evidencing their consent to X becoming the child's father. The fact that the forms do not contain the wording that is to be found in in Forms WP and PP is no more than a reflection of administrative incompetence on the part of the Trust. What matters is the substance and total effect of the documents, which clearly express the intention of the couple to be treated as full and equal legal parents. Had they been asked at the time what they were doing in signing these documents, they would have said that they were doing what was necessary to achieve this parenthood. Had the clinic been asked what the couple was doing in signing these documents, it would have agreed. The difficulty here only arose because the clinic failed to give the couple the recommended tools for the job, but I find that the couple still managed to get the job done with the tools that they were given.

27.I recognise that this conclusion is based on somewhat different IC forms than those considered in other cases, but nevertheless find that the agreed fatherhood condition in s.37 is satisfied in this case. It is an outcome that conforms with the twin pillars of the legislation informed consent and child welfare.

28.There will accordingly be a declaration that X is as in law (as he is in life) the child's legal parent, alongside Y. I will make a separate order in relation to the costs that are to be paid by the Trust, and will direct that the file is not to be accessed by anyone without the permission of the President of the Family Division for the time being. ____________________

View post:
B v B (Fertility Treatment - Paperwork Error) [2017] EWHC 599 (Fam) - Family Law Week

European Patent Office to grant UC a broad patent on CRISPR-Cas9 – UC Berkeley

The European Patent Office (EPO) has announced its intention to grant a broad patent for the revolutionary CRISPR-Cas9 gene-editing technology to the University of California, the University of Vienna and Emmanuelle Charpentier.

A model of the Cas9 protein cutting a double-stranded piece of DNA.

The university is thrilled with this important EPO decision, which recognizes the pioneering work of Jennifer Doudna, Emmanuelle Charpentier and their teams as the CRISPR-Cas9 inventors, and also recognizes that the original patent application covers a wide range of cell types, including human cells, said Edward Penhoet, who was recently appointed a special advisor on CRISPR to the UC president and UC Berkeley chancellor. Penhoet, the cofounder and former CEO of Chiron Corp., is the associate dean of biology at UC Berkeley and a professor emeritus of molecular and cell biology.

The EPO patent will cover the single-guide CRISPR-Cas9 technology in cells of all types. The technology was invented by Jennifer Doudna, a UC Berkeley professor of molecular and cell biology, Charpentier, now director of the Max Planck Institute for Infection Biology in Berlin, and their colleagues. Applications include treatment of various human diseases, as well as veterinary, agricultural and other biotech applications. The European patent would cover some 40 countries, including France, Germany, Italy, Spain, the Netherlands and Switzerland.

The EPO has stated its intent to grant a patent with claims that encompass all cells, despite objections from third parties, including the Broad Institute, a joint research institute of Harvard University and the Massachusetts Institute of Technology.

We are excited that this patent will issue based on the foundational research we published with Emmanuelle Charpentier and the rest of our team. We look forward to the continued applications of gene-editing technology to solve problems in human health and agriculture, said Doudna, who is a Howard Hughes Medical investigator at UC Berkeley.

The CRISPR-Cas9 tool allows the precise editing of genes, and has been used in thousands of laboratories around the world to target and cut desired sequences of DNA, analogous to cutting and pasting letters or words with a word processor. This technology has already revolutionized the study of genetic diseases, and has spawned promising new therapies for blood diseases, AIDS and cancer.

What is CRISPR-Cas9 and how does it work? How do we edit genes? Jennifer Doudna, biochemist at UC Berkeley, explains (UC Berkeley video by Roxanne Makasdjian and Stephen McNally)

The EPOs notice of intent to issue the patent, as well as the UK Intellectual Property Offices grant of two similarly broad patents, are precedents for Doudna and Charpentier to receive wide-ranging patents in many countries, since many look to EPO and UK decisions for guidance in granting patents.

The UC patent application to the EPO was substantially the same as the UC patent application filed in the United States. In the U.S., UC claims covering the use of single-guide CRISPR-Cas9 technology in any setting were found to be allowable by the U.S. Patent & Trademark Office, and were placed in an interference with patents owned by the Broad Institute that cover use of the technology in eukaryotic cells. An interference is a formal legal proceeding before the Patent Trial and Appeal Board (PTAB) to determine who was the first to invent.

In a February ruling, the PTAB terminated the interference between the UC application and Broad patents, determining that the claims of the two parties did not constitute the same invention and, accordingly, the PTAB did not determine which party first invented the use of the technology in eukaryotic cells.

We disagree with the recent PTAB decision to terminate the interference between claims of the UC and the Broad Institute, and we are keeping all of our options open, including the possibility of an appeal, Penhoet said. We remain confident that when the inventorship question is finally answered, the Doudna and Charpentier teams will prevail.

The inventors listed on the European patent are Doudna; Charpentier; Martin Jinek, now at the University of Zurich; Krzysztof Chylinski of the University of Vienna; Wendell Lim of UC San Francisco; Lei Stanley Qi, now at Stanford University; and Jamie Cate, a UC Berkeley professor of molecular and cell biology.

RELATED INFORMATION

Excerpt from:
European Patent Office to grant UC a broad patent on CRISPR-Cas9 - UC Berkeley

How non-muscle cells find the strength to move – Phys.org – Phys.Org

March 29, 2017 Figure: Visualization of myosin II filament stacks (yellow) with cross-linking protein alpha-actinin-1 (blue) in fibroblast cells using structured illumination microscopy. Myosin II filaments alternate with apha-actinin enriched domains along actin stress fibre. Credits: Mechanobiology Institute, Singapore

Researchers from the Mechanobiology Institute, Singapore (MBI) at the National University of Singapore have described, for the first time, the ordered arrangement of myosin-II filaments in actin cables of non-muscle cells. This work was published in Nature Cell Biology in January 2017.

Ordered arrangement of myosin-II filaments defined in non-muscle cells

The twitching contractions of our muscle cells are well known. They can be detected just weeks after conception as the embryonic heart begins beating. Muscle cell contractility is produced from interactions between protein-based cables of the cytoskeleton and small molecular motor proteins known as myosins.

There are over 200 types of cells within the human body, and not all need to repeatedly contract. Despite their distinct functions, nearly all cells contain the same basic protein components found in muscle cells. Importantly, most cells also exhibit some degree of slow contractility. Fibroblasts are one such example. Found in connective tissue, these cells produce the material that surrounds all cells, and ultimately defines tissue shape. Importantly, fibroblasts are also known to remodel this material, and for this, they need strength to pull against their environment.

To investigate the organisation of the cytoskeleton and its associated motor proteins in non-muscle cells, researchers from MBI analysed fibroblasts using a form of super resolution microscopy known as Structured Illumination Microscopy (SIM).

The researchers, who were led by Professor Alexander Bershadsky and Assistant Professor Ronen Zaidel-Bar, focused their investigation on the assembly of the cytoskeleton. Along with providing structural support to the cell, the cytoskeleton can also buffer stresses from the external microenvironment and give cells the power to contract and move through a tissue. These processes are possible due to the continual assembly and disassembly of the protein cables, and due to the generation of force as motor proteins pull on these cables.

When the cytoskeleton was viewed in living fibroblasts, Dr Shiqiong Hu, a postdoctoral researcher at MBI, and colleagues, discovered unique, organised patterns of motor protein filaments within large protein cable-like structures known as stress-fibres. These cables form dynamically and often bridge sites where the cells are interacting with the microenvironment.

Like ropes, these cables are made up of many individual filaments, held together by various cross-linking proteins. By watching the cytoskeleton form over time, the researchers observed how myosin-II filaments arranged into stacks that ran perpendicular to the large parallel stress fibres. These stacks alternated with regions of the 'cross-linking' protein a-actinin, which tethers individual filaments together to produce the protein cable.

How myosin-II filaments come to be stacked together within the bundled stress fibres, remains to be fully defined, however one observation from this study that may hold the answer, is the long range movement of myosin-II filaments towards each other. As the researchers propose, this attraction may result from contractile or elastic forces generated by the myosin filament stacks, which can transmit through the surrounding cytosol to individual filaments that are otherwise isolated.

The stacking of myosin-II filaments in non-muscle cells like the fibroblast is an intriguing element in the self-organisation of the cytoskeleton, and overall architecture of the cell. Fibroblast function requires the cell to be able to stretch, generate cytoskeletal protrusions and move to other regions of the connective tissue. The assembly and organisation of myosin-II into stacks permits the fibroblast to fulfill these cellular processes.

Even in non-muscle cells, the architecture of the cytoskeleton is specialised for force generation and sensing. The organisation of the cytoskeleton in non-muscle cells is strikingly similar to that in muscle cells. In both cases contractile and elastic forces are integral in establishing a functional cytoskeleton, and once formed, a pattern of repeating protein-based contractile proteins becomes evident. However, unlike in muscle cells, these structures continuously assemble and disassemble in non-muscle cells, allowing them to adapt their function, shape, and direction of movement according to the environment they find themselves in.

As observed in this study, even non-muscle cells require the strength to pull against their surroundings, and fight their way through often sticky environments. This strength comes from a highly refined system of filaments and motor proteins. Although not as strong as those found in muscle cells, their organisation in non-muscle cells allows them to remain responsive to changes in the environment, whilst providing just the right amount of force to carry out their functions.

Explore further: Cellular podiatry understanding how cells form feet

More information: Shiqiong Hu et al. Long-range self-organization of cytoskeletal myosin II filament stacks, Nature Cell Biology (2017). DOI: 10.1038/ncb3466

A study carried out by a team of researchers from the labs of Professor Alexander Bershadsky at the Mechanobiology Institute, Singapore at the National University of Singapore and Professor Gareth E Jones at King's College ...

Muscle-specific protein cofilin-2 controls the length of actin filaments in muscle cells.

At the molecular level, muscle contraction is defined by myosin molecules pulling actin filaments. New electron cryomicroscopy images with unprecedented resolution taken by researchers at Osaka University reveal unexpectedly ...

Understanding how tiny molecular motors called myosins use energy to fuel biological tasks like contracting muscles could lead to therapies for muscle diseases and cancers, says a team of researchers led by Penn State College ...

Scientists at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria and at the University of Cologne, Germany have discovered the molecular basis underlying the patterned folding and assembly of muscle proteins. ...

Scientists from the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany have discovered a new, hitherto unknown mechanism of Salmonella invasion into gut cells: In this entry mode, the bacteria exploit ...

About 80 million years ago, a group of bees began exhibiting social behavior, which includes raising young together, sharing food resources and defending their colony. Today, their descendantshoney bees, stingless bees ...

UBC scientists have scanned the genome of cannabis plants to find the genes responsible for giving various strains their lemony, skunky or earthy flavors, an important step for the budding legal cannabis industry.

Playing music to captive chimpanzees has no positive effect on their welfare, researchers have concluded.

The width of a bird's visual binocular field is partially determined by the size of the blind area in front of its head, according to a study published March 29, 2017 in the open-access journal PLOS ONE by Luke Tyrrell and ...

(Phys.org)A trio of researchers with Oregon State University and Monmouth University has conducted experiments with cats, and has found that they appear to like humans more than expected. In their paper published in the ...

Unlike most animals, sea lampreys, an invasive, parasitic species of fish damaging the Great Lakes, could become male or female depending on how quickly they grow, according to a U.S. Geological Survey study published today.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the original post here:
How non-muscle cells find the strength to move - Phys.org - Phys.Org

NSF Graduate Research Fellowships | UDaily – University of Delaware – UDaily

A dozen University of Delaware students (undergraduate and graduate) and alumni have won National Science Foundation Graduate Research Fellowships as the prestigious competition marks its 65th year. Fourteen others received honorable mention designations.

The awards -- for which more than 13,000 applicants competed this year -- include three years of funding at $34,000 per year, plus $12,000 in cost-of-education allowances to the school for study leading to a master's or doctoral degree in science and engineering. The total of these awards is almost $1.4 million -- a significant boost for the students and their research.

"Research is incredibly important," said Dianna Kitt, a senior majoring in environmental engineering and one of UD's 12 winners. "On a large scale, research is what drives our society and allows us to create new technologies and processes that protect humans, animals and the environment. On a smaller scale, research pushes you as an individual to think outside of the book and answer problems that no one else has answered before."

The awards make a powerful statement about these students, said Donald Watson, associate professor of chemistry and biochemistry and the department's associate chair for graduate studies. That department had four winners - two undergraduates and two graduate students - including doctoral student Sarah Krause in Watson's research group.

"This includes all fields of science and engineering and these awards go to extraordinarily high-quality students," he said. "It recognizes their ability and frees students to do science. And getting multiple awards in a single year is a mark of quality for our program."

Nationally, there were 2,000 winners (about 15 percent of all applicants), representing 449 different schools, all 50 states, the District of Columbia and other U.S. territories. Winners included 1,158 women, 498 individuals from underrepresented minority groups and 726 undergraduate seniors.

"This is one of the most prestigious awards a student can get," said Julie Maresca, assistant professor of civil and environmental engineering and Kitt's faculty mentor. "These awards are highly competitive and truly a recognition of the students' potential for future success.

"The students who get these fellowships have demonstrated not only that they are among our top students, but also that they can convincingly propose a multiyear research project and are committed to broadening participation in their fields."

* Ian Berke of Albany, New York, who earned his bachelor's in biomedical engineering in 2016 and now is pursuing a doctoral degree in biomedical engineering at Washington University in St. Louis, Missouri.

"In my sophomore year at UD, I had a sports-related knee injury that required surgery (ACL tear). This got me interested in orthopedic research and I was paired with Christopher Price, assistant professor in biomedical engineering, for a summer scholar research opportunity, in imaging. During the summer and in the following year or so we imaged bone and cartilage using refractive index matching techniques. Dr. Price really sparked my interest in the field and showed me the many avenues researchers were taking to combat osteoarthritis."

* Hannah Clipp of Bel Air, Maryland, who earned two bachelor's degrees -- in wildlife and fisheries resources and multidisciplinary studies -- at West Virginia University and is pursuing a master's degree in wildlife ecology at UD.

The focus of her research is bird migration and stopover ecology and bird conservation.

* Jonathan Galarraga of Belcamp, Maryland, a du Pont Scholar who earned an honors bachelor's degree in chemical engineering in 2016 and will pursue his doctorate at the University of Pennsylvania, where he will study tissue engineering, biomaterials, 3D-printing and cartilage repair.

"Biomaterials are changing possibilities for medicine and healthcare across the world because they provide new avenues for exploring prospective therapeutics, modeling disease pathology and assessing drug toxicity.In my Ph.D. thesis, I will develop new materials approaches for tissue repair through rational material design and impact society through new product development.As a Ph.D. student in Dr. Jason Burdicks Polymeric Biomaterials Lab at the University of Pennsylvania, I am eager to establish strong relationships with leading experts in the country so that I may design and deliver clinically viable biomaterials."

At UD, Galarraga worked in the research group of Christopher Kloxin, assistant professor of chemical and biomolecular engineering.

"Throughout my time in the CJK lab, I gained a strong appreciation for collaborations in research, developed intimate knowledge of the materials science research landscape, and enjoyed the privilegeof learning from many great mentors.

"The aims of my career are to conduct research on biomaterials and bring clinically viable biotechnology to market while teaching as a university professor. In doing so, I will improve the quality of life for people with disabilities and diseases, increase the U.S. competitiveness in the growing biomedical device industry and improve the prospects for future biomedical research. In addition to commercially developing these technologies, I will employ my bioengineering expertise to help develop and implement policies that will ensure that future biomaterials are readily accessible and disseminated to underserved patient populations."

* Nicholas Geneva of Owings, Maryland, an honors degree candidate who is completing his bachelor's degree in mechanical engineering and will pursue a doctoral degree, continuing his work integrating state-of-the-art computer technology and engineering at UD.

"Working with Dr. Lian-Ping Wang [professor of mechanical engineering] and his graduate students is largely the reason why I decided to pursue a Ph.D. His work has shown me that the integration of state-of-the-art computer hardware and engineering is a very important challenge that is facing the scientific community today. Computing, whether through traditional CPUs or other hardware accelerators, is becoming ever more powerful, but exploiting this power effectively to solve the difficult engineering problem is by no means trivial."

* Rebekah Houser of Newark, Delaware, who earned a bachelor's degree in electrical engineering and will continue research on vehicle-to-grid technology and firmware for an infrared scene projector.

"Electric vehicles equipped with vehicle-to-grid technology can provide valuable services to electric power generation and distribution systems. These services promote adoption of electric vehicles and facilitate increased incorporation of renewable resources into the electric power grid. Infrared scene projectors enable more efficient testing of infrared imaging systems that serve as critical tools for first responders, law enforcement and military personnel."

* Dianna Kitt of Aberdeen, Maryland, a du Pont scholar who is completing her bachelor's honors degree with distinction in environmental engineering and will pursue graduate-level research in water treatment.

"I grew up near the Chesapeake Bay so I have always been passionate about clean water and the environment. When I was in high school, I was inspired by my AP biology teacher (who was actually a retired research scientist) to work in a research lab for the first time and I fell in love with research. I knew that I wanted to pursue my passion for improving the environment as my career, and I knew that a career in environmental engineering research would allow me to not only study the environment but also develop techniques and processes to protect it."

* Jodi Kraus of Monument, Colorado, who earned her bachelor's degree at Drexel University and is a second-year grad student in chemistry and biochemistry at UD.

In the laboratory of Tatyana Polenova, professor of chemistry and biochemistry, she has focused on determining the atomic-level structure and dynamics of actin-associated protein assemblies using the technique Magic Angle Spinning NMR.

"I was drawn to using solid-state NMR spectroscopy to study large protein assemblies because the scientific understanding of fundamental biological processes is rapidly expanding, and it is of utmost importance to continue developing new methodologies to study these complex systems. I believe that in order to fully understand these biological processes and identify new potential drug targets (in the case of disease), we must investigate their most basic properties. Additionally, I am interested in methods development and instrumentation because I personally find it gratifying to track the exact physical dynamics which correlate to larger functional roles within proteins."

* Sarah Krause of Harford County, Maryland, who earned her bachelor's degree in chemistry at Towson University and is pursuing her doctorate in organic chemistry at UD in Donald Watson's research group.

The focus of her research is chemical synthesis and catalysis.

* Andrew Kuznicki of Boston, Massachusetts, who is majoring in chemistry.

His research has been in the inorganic chemistry lab of Joel Rosenthal, associate professor of chemistry and biochemistry.

* Peter Sariano of Collegeville, Pennsylvania, an honors degree candidate who is majoring in biomedical engineering and plans to pursue research in tissue engineering.

"Biomedical research is the foundation for medical discovery. Research drives our understanding of disease and allows us to develop treatments to address unmet clinical needs."

* Hannah Wastyk of Palmyra, Pennsylvania, a du Pont Scholar and honors degree candidate majoring in biochemistry with a minor in biochemical engineering.

"What excites me most about research on human disease is that the body is a system more perfect than any we could possibly engineer. Our immune system is the most complex line of defense we possess, and treating diseases through regulation of its already existing cellular processes to control aberrant signaling is a technique that holds almost unlimited possibilities.

"The concept of growth has always been a passion I continually strive for. Research, both in practice and in mindset, perfectly embodies this endless cycle of growth through the creation of knowledge starting with basic research and applying it to solve real-world problems through engineering."

* Kathryn Wheeler of Boone, North Carolina, a du Pont Scholar and honors degree candidate who is earning her bachelor's degree in environmental science and will pursue a doctoral degree at Boston University's Department of Earth and the Environment.

"I am interested in how climate change is altering forest phenology (seasonality) and how the timing of the seasons affects the forest ecosystem and global ecosystems. Specifically, at Boston University I will be working on a project that uses ecosystem forecasting to identify the holes in our understanding of phenology and seasonal variation in carbon and energy transfers between the biosphere and atmosphere. With warmer global temperatures, the growing season is expected to be lengthened in many ecosystems. A longer growing season has the possibility of increasing the amount of carbon dioxide that trees take away from the atmosphere, which consequently would likely alleviate global climate change. In order to improve the accuracy of climate change predictions, it is necessary for us to better understand forest phenology and how it affects and is affected by climate change.

Research with Delphis Levia, professor of ecohydrology and chair of UD's Department of Geography, and doctoral student Janice Hudson introduced her to phenology.

"I became fascinated by the idea that something as seemingly simple as changing the timing of the seasons can have profound impacts on ecosystems. I became particularly interested in how phenology can then affect climate change through an ecosystems ecology course I took with Dr. Rodrigo Vargas [assistant professor of plant and soil sciences] this fall."

Hunter Bachman, mechanical engineering, an honors degree candidate, now at Duke University

Rabae Bounoua, psychology

Christopher Bresette, engineering, an honors degree candidate

Kamil Charubin, chemical engineering

Patrick Cronin, electrical and computer engineering

Nathan Hamilton, chemical engineering, an honors degree candidate

Alyssa Hull, chemistry and art conservation, a double honors degree recipient, now at Duke University

Joshua Lansford, chemical engineering

Charles McCutcheon, chemical engineering, now at the University of Minnesota

Bonnie McDevitt, environmental engineering, an honors degree recipient, now at Penn State University

Alexander Mitkas, chemical engineering

Samuel Modlin, neuroscience, now at San Diego State University Foundation

Lacey Perdue, bioengineering, an honors degree candidate

Jacob Wilmot, biology and neuroscience, an honors degree recipient, now at the University of California-Davis

A complete list of those offered the fellowship for 2017 is available on FastLane. For general information about the program, visit NSF's GRFP website.

Read this article:
NSF Graduate Research Fellowships | UDaily - University of Delaware - UDaily

The anatomy of a bodyboard – SurferToday

29 March 2017 | Bodyboarding

Modern bodyboards are advanced wave riding crafts. They are designed and shaped to deliver optimal performances in all types of ocean conditions. All attributes of a bodyboard have been fine-tuned so that each model serves a precise requirement.

Today, a bodyboard is way more than a simple waterproof foam board. There's science, knowledge, and experimentation in it. The most popular bodyboard manufacturers take all variables into consideration before releasing their portfolio.

Understanding how a bodyboard works will help you choose the right model for your weight and height, and level of experience. If you still have doubts, consult the bodyboard size chart.

Bodyboards have several fundamental properties. They are as follows:

The Core

It's the bodyboard's constituent foam material. There are two main types of core: Polyethylene (PE), Polypropylene (PP), and Extruded Polystyrene (EPS). The core gives the overall shape of the board, and play a critical role in wave riding performance.

The Deck

It's the bodyboard's top skin and the material that will cushion the impact of the sport's radical maneuvers. The high-end models come with PE decks, but some manufacturers also use crosslink formula.

The Slick

It's the bodyboard's bottom skin, and it should reduce the drag when the board is in contact with the surface of the water, and provide flexibility. The main types of materials used in the deck are Surlyn and HDPE.

The Channel

Channels are canals located near the tail on the bodyboard's slick. The provide extra grip on the face of the wave.

The Rail

It's the bodyboard's steering wheel and has an impact in control and speed. The two main types of rails are the 60/40 and the 50/50.

The Nose

It's the bodyboard's top and has an impact on the wave riding experience. Narrow noses mean a loose control and higher speed, while a wider nose performs better in big wave conditions.

The Rocker

It's the bodyboard's natural curve. A nearly flat rocker makes the board go faster and is harder to control; a board with too much rocker has a lot of drag, but it can be easier to navigate.

The Wide Point

The area of the bodyboard where the contours change their direction. It defines the overall template and the width distribution of the board. For a loose feel, get a board with a lower wide point; for control and speed pick a model with a higher wide point.

The Thickness

Thinner bodyboards are agile and have increased maneuverability, but they are also less buoyant and fast than thicker models with their extra volume.

The Tail

It's the bodyboard's wheel and provides more or less control and speed depending on their shape. The most common tail designs are the bat tail and the crescent tail.

The Stringer

It's the bodyboard's skeleton and provides control, strength, and stiffness. The tube is generally made of fiberglass and is inserted into the core of the board.

Original post:
The anatomy of a bodyboard - SurferToday

New England Allergy, Asthma & Immunology PC Hosts 23-Nation Delegation of Top Healthcare Officials – PR Newswire (press release)

The delegation was comprised of Secretaries and Assistant Secretaries of Health, Program Directors, CEOs, Program Officers, Medical Officers, and many professors and researchers from:

"We are honored and equally humbled to host a delegation of this caliber at our home institution," said Dr. Thomas F. Johnson, Founder, Owner, and Chief Medical Officer of New England Allergy. "This speaks volumes to our commitment to promote the best health standards and to our full endorsement of a borderless world where every nation serves as a building block in global health initiatives to help prevent and combat disease."

"New England Allergy, Asthma & Immunology is pioneering a global system of collaboration across geographies and across medical disciplines to facilitate knowledge transfer, preventative screening, treatment, and efficient healthcare delivery systems," said George Kassas, CEO of Bireme Systems LLC, the Business Managing firm of New England Allergy. "This distinguished delegation's visit reaffirms New England Allergy's mission to welcome patients from all over the world to receive the very best care from many different medical subspecialties centered from our growing, premier facility."

New England Allergy, Asthma & Immunology P.C. http://www.newenglandallergy.com is located in North Andover, M.A. with offices in Lowell, M.A., Newburyport, M.A., Salem, N.H., Hampstead, N.H., and Hooksett, N.H. To learn more about the services offered by the practice, please visit http://www.newenglandallergy.com.

Media Contact:George Kassas+1508-523-4432George.kassas@newenglandallergy.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-england-allergy-asthma--immunology-pc-hosts-23-nation-delegation-of-top-healthcare-officials-300429806.html

SOURCE New England Allergy, Asthma & Immunology P.C.

Home

Original post:
New England Allergy, Asthma & Immunology PC Hosts 23-Nation Delegation of Top Healthcare Officials - PR Newswire (press release)

‘Numerous barriers’ in accessing EU infertility services – euronews

A new EU report claims there are numerous barriers in accessing infertility services across the European Union.

The document, produced by Fertility Europe and the European Society of Human Reproduction and Embryology, shows around 25 million EU citizens are affected by infertility.

It also highlights that fertility rates vary across the nine countries looked at, with the lowest in Spain and Poland and the highest in France. But even the highest rate falls short of the population stabilisation rate of 2.1 live births per woman.

A Romanian MEP, who has hosted a debate in Brussels, says Europe faces a huge demographic problem.

In order to resolve this issue, its necessary to look to the internal policy and fertility policy must be internal policy in all member states, said Norica Nicolai.

Born in Britain in 1978, Louise Brown was the worlds first so-called test tube baby. IVF used to help her mother who couldnt conceive naturally. It was revolutionary, but highly controversial.

Now 38, Louise has been in Brussels for the release of the report.

Before mum was pregnant with me, mum actually went to the doctors with depression. And the doctor underlined the fact that she couldnt get pregnant that was causing the depression, she told Euronews.

So, its just the awareness for people to realise that its not just for mums and dads to have a baby, its creating families.

IVF the process of fertilising an egg with sperm outside the body remains controversial.

What we would like to see is much more restorative medicine and therapies, which actually address the problem of infertility at its source, not more IVF, said Mark Bhagwandin, from the UK-based Life charity.

Louise says all women in the EU should be offered IVF, if they cant conceive naturally. She thanks it for her existence, and has gone on to have a family of her own.

The Policy Audit on Fertility looked at the Czech Republic, France, Germany, Italy, Poland, Romania, Spain, Sweden and the UK. Click here for full document.

Visit link:
'Numerous barriers' in accessing EU infertility services - euronews

8 Things That Need to Happen for Grey’s Anatomy to Get Out of Its Slump – Cosmopolitan.com

Getty

Advertisement - Continue Reading Below

It pains me to type this, but here goes: This season of Grey's Anatomy hasn't been very good and the timing of that drop-off in quality couldn't be worse. We need smart, feminist, compelling shows to escape into, now more than ever! While it might be too late for the show to course-correct in season 13, it's not too late to start thinking about how season 14 could be better. Here are eight things Grey's Anatomy should do to shake off the cobwebs and recapture its magic.

Perhaps Ellen Pompeo needed to work less after the birth of her infant son, which would be totally understandable but her storylines should still count. Meredith is the Grey in Grey's Anatomy and she deserves more than what she's getting. Last season, we got to see her adjust to a world without McDreamy and cope with a life-altering assault. This season, we've seen her worry about Alex, get suspended from the hospital, and spin her wheels in a never-ending flirtation with Riggs. Ellen continues to nail the material she's given but she needs more to work with.

I've hated seeing characters like Webber, Alex, Bailey, and Arizona mishandled this season. Where has Alex been since he was released from prison? Why has the ball been dropped on digging into his relationship with Jo? Why have Webber and Bailey and Arizona spent so much time locked into the drama with Eliza, who at this point feels more like a plot device than a person? If it takes doing more bottle-style episodes, like the one with Jo, Arizona, and Bailey at the women's hospital, run with that!

Advertisement - Continue Reading Below

These days, they're fully each other's person, and that's something we haven't really seen developed or explored this season. We know they've gotten much, much closer, and the subtext is that's a result of Derek's death and Alex's arrest. That needs to become less of a background story. Meredith's honest, compelling voicemail to Alex when he was considering taking a plea deal was one of the best moments of the season, and we need more of that. They don't have to hook up (although I maintain that they are an end-game couple), but since the scenes they have together are one of the only elements of Grey's that continues to pop, the show needs to spend more time with them and, not to harp on this, with Meredith and Alex as individuals too.

Advertisement - Continue Reading Below

Remember when Grey's used to be all about doctors pulling one another into on-call rooms for nonstop hookups? I rewatched the Grey's pilot this week for the 12th anniversary of its airing (!!), and even though the characters barely knew each other, the show was crackling with sexual tension. I know a natural response to this might be that the characters are more mature now, which might explain the drop-off in sexual hijinks, but people in their 40s need hot sex too! And adding some younger characters and then actually taking the time to flesh them out (pun absolutely intended) might help with this as well.

Where are the hospital shootings? Where are the plane crashes? Where are the cut LVAD wires? So far, the major drama this season has come from "suspense" around Alex's arrest come on, was the series really going to put him in prison for 10 years? and the staffing shakeup in the residency director position. Grey's is literally asking us to stay invested in what amounts to an administrative staffing challenge for months, while turning major characters into cartoon-villain versions of themselves in the process. As it's done so, it's relied heavily on the stories of patients to drive the episodes, putting our characters' running stories in the backseat. I've loved some of the patient-driven storytelling the season, but it's frustrating when that comes at the cost of ignoring our favorite characters.

Advertisement - Continue Reading Below

This one might sound overly specific, but aside from a handful of random patients and guest stars, Grey's has never featured a romantic relationship between men. There aren't too many unique romantic angles left for the show to explore but really taking the time to develop a gay male relationship would give the show a new dimension (and possibly allow for more scenes with hot dudes with their shirts off, which the show has been sorely lacking lately).

Remember when Grey's made a huge deal out of the fact that Leah Murphy would be rejoining the cast? She showed up in a few random episodes, was barely used, and then disappeared. By contrast, Maggie's mom has only been in two episodes, but the show has managed to make her three-dimensional through a genuinely compelling story, which has given us a long-overdue chance to get to know Maggie better, too. More moms, fewer Murphys, please.

Advertisement - Continue Reading Below

If I squint and tilt my head to one side, I can see how maybe Grey's is trying to use Owen and Amelia's story to point out that in real life, couples fight and that's a normal part of relationships. But Owen and Amelia only fight. Do they even like each other?! They've been on a cycle of ignoring each other and then yelling at each other for weeks now, and it's tiresome. To make matters worse, we've seen Owen have nearly identical fights with Cristina, which means Kevin McKidd has been stuck doing the same material for years. Again, maybe Grey's is trying to tell stories about how Owen has patterns that sabotage his relationships, and I applaud their effort to be realistic in that regard. But it's gotten old and I'm over it.

Follow Lauren on Twitter.

See original here:
8 Things That Need to Happen for Grey's Anatomy to Get Out of Its Slump - Cosmopolitan.com